STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma

This study compares two treatment combinations for people with liver cancer (hepatocellular carcinoma, or HCC) that cannot be surgically removed. Both groups receive STRIDE — a combination of two immunotherapy drugs (durvalumab and tremelimumab). One group also receives lenvatinib, a targeted therapy that blocks blood vessel growth in tumors. Researchers want to know if adding lenvatinib improves outcomes. **You may be eligible if:** - You are 18 or older and weigh more than 30 kg - You have confirmed liver cancer (HCC) that cannot be surgically removed - You have not received prior systemic (whole-body) treatment for liver cancer - Your liver function is adequate (Child-Pugh class A or low-B) - Your general health is good enough (ECOG performance status ≤1) - Your life expectancy is at least 12 weeks **You may NOT be eligible if:** - You have received prior systemic therapy for liver cancer - Your liver function is severely impaired - You have another active cancer requiring treatment - You have autoimmune disease or conditions that make immunotherapy unsafe - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.